James Rolke - 25 Feb 2023 Form 4 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Role
Chief Executive Officer, Director
Signature
/s/ J.P. Galda, as attorney-in-fact for James Rolke
Issuer symbol
REVB
Transactions as of
25 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 15:08:00 UTC
Previous filing
20 Jan 2022
Next filing
13 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REVB Stock Option (Right to Buy) Award $0 +2,542 $0.000000* 0 25 Feb 2023 Common Stock 2,542 $49.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.